NUWE
Nuwellis Inc
$
2.870
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
2.870
Open
2.750
VWAP
2.81
Vol
37.90K
Mkt Cap
2.59M
Low
2.750
Amount
106.34K
EV/EBITDA(TTM)
--
Total Shares
18.05M
EV
-2.93M
EV/OCF(TTM)
--
P/S(TTM)
0.02
Nuwellis, Inc. is a commercial-stage medical technology company. The Company is focused on developing, manufacturing, and commercializing medical devices used in ultrafiltration therapy, including the Aquadex FlexFlow and the Aquadex SmartFlow systems (collectively the Aquadex System). The Aquadex SmartFlow system is indicated for temporary or extended use in adult and pediatric patients weighing 20 kilograms or more whose fluid overload is unresponsive to medical management, including diuretics. The Aquadex System is designed to remove excess fluid from patients suffering from fluid overload who have failed diuretic therapy. The Aquadex System consists of a console, which is a piece of equipment containing electromechanical pumps and a liquid crystal display (LCD) screen; a one-time disposable blood circuit set, which is an integrated collection of tubing, filters, sensors, and connectors that contain and deliver the blood from and back to the patient, and a disposable catheter.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q2
FY2025Q3
FY2025Q4
2.20M
+0.27%
--
--
2.50M
+5.62%
--
--
2.52M
+8.7%
--
--
Estimates Revision
The market is revising No Change the revenue expectations for Nuwellis, Inc. (NUWE) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by -44.81%.
Revenue Estimates for FY2025
No Change
0.00%
In Past 3 Month
EPS Estimates for FY2025
No Change
0.00%
In Past 3 Month
Stock Price
Go Down
-44.81%
In Past 3 Month
Valuation Metrics
The current forward P/E ratio for Nuwellis Inc (NUWE.O) is -0.04, compared to its 5-year average forward P/E of -0.73. For a more detailed relative valuation and DCF analysis to assess Nuwellis Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-0.73
Current PE
-0.04
Overvalued PE
-0.13
Undervalued PE
-1.33
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
0.20
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.56
Undervalued EV/EBITDA
-0.16
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
Strongly Overvalued
5Y Average PS
0.95
Current PS
2.87
Overvalued PS
1.88
Undervalued PS
0.03
Financials
Annual
Quarterly
FY2025Q2
YoY :
-21.38%
1.73M
Total Revenue
FY2025Q2
YoY :
+25.26%
-2.91M
Operating Profit
FY2025Q2
YoY :
+62.50%
-12.55M
Net Income after Tax
FY2025Q2
YoY :
+223.40%
-2.56K
EPS - Diluted
FY2025Q2
YoY :
-24.37%
-2.10M
Free Cash Flow
FY2025Q2
YoY :
-17.33%
55.54
Gross Profit Margin - %
FY2025Q2
YoY :
+106.68%
-727.71
Net Margin - %
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
NUWE News & Events
Events Timeline
2025-09-30 (ET)
2025-09-30
08:54:59
Nuwellis announces 92% survival rate for children with AKI in ULTRA-Peds registry
2025-09-18 (ET)
2025-09-18
09:03:39
Nuwellis Secures New U.S. Patent Strengthening Vivian Pediatric Device
2025-09-09 (ET)
2025-09-09
09:06:31
Nuwellis Reveals NIH Grant of $3M for KBT Over Multiple Years
Sign Up For More Events
Sign Up For More Events
News
7.5
09-17Yahoo FinanceNuwellis, Inc. Engages in Virtual Investor Segment "What This Means"
5.0
09-04NewsfilterNuwellis Launches 24-Hour Aquadex™ Circuit for Enhanced Fluid Management in Hospital Outpatient and Short-Term Care Settings
9.0
08-21NewsfilterNuwellis Secures FDA 510(k) Approval for Innovative Dual Lumen Extended Length Catheter
Sign Up For More News
People Also Watch
FAQ
What is Nuwellis Inc (NUWE) stock price today?
The current price of NUWE is 2.87 USD — it has increased 3.24 % in the last trading day.
What is Nuwellis Inc (NUWE)'s business?
What is the price predicton of NUWE Stock?
What is Nuwellis Inc (NUWE)'s revenue for the last quarter?
What is Nuwellis Inc (NUWE)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Nuwellis Inc (NUWE)'s fundamentals?
How many employees does Nuwellis Inc (NUWE). have?